|  Help  |  About  |  Contact Us

Publication : SerpinB13 antibodies promote ? cell development and resistance to type 1 diabetes.

First Author  Kryvalap Y Year  2021
Journal  Sci Transl Med Volume  13
Issue  588 PubMed ID  33827974
Mgi Jnum  J:376166 Mgi Id  MGI:8269065
Doi  10.1126/scitranslmed.abf1587 Citation  Kryvalap Y, et al. (2021) SerpinB13 antibodies promote beta cell development and resistance to type 1 diabetes. Sci Transl Med 13(588):eabf1587
abstractText  Pancreatic endocrine cell development is dependent on the rescue of the neurogenin3 (Ngn3) transcription factor from repression by Notch. The signals that prevent Notch signaling, thereby allowing the formation of pancreatic endocrine cells, remain unclear. We show that inhibiting serpinB13, a cathepsin L (CatL) protease inhibitor expressed in the pancreatic epithelium, caused in vitro and in vivo cleavage of the extracellular domain of Notch1. This was followed by a twofold increase in the Ngn3(+) progenitor cell population and enhanced conversion of these cells to express insulin. Conversely, both recombinant serpinB13 protein and CatL deficiency down-regulated pancreatic Ngn3(+) cell output. Mouse embryonic exposure to inhibitory anti-serpinB13 antibody resulted in increased islet cell mass and improved outcomes in streptozotocin-induced diabetes at 8 weeks of age. Moreover, anti-serpinB13 autoantibodies stimulated Ngn3(+) endocrine progenitor formation in the pancreas and were associated with delayed progression to type 1 diabetes (T1D) in children. These data demonstrate long-term impact of serpinB13 activity on islet biology and suggest that promoting protease activity by blocking this serpin may have prophylactic potential in T1D.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

19 Bio Entities

6 Expression